Getinge AB (publ) (GETIB) Earnings Call Transcripts

Getinge AB (publ)'s Latest Earnings Call - Q1 FY2026

In Q1 2026, Getinge AB reported organic net sales growth of 0.8%, driven by strong performance in Life Science and Surgical Workflows. Adjusted EBITDA was SEK 824 million, reflecting a margin of 11.1%, impacted by currency and tariff headwinds totaling SEK 226 million. Management maintained guidance for organic net sales growth of 3% to 5% for the fiscal year, indicating confidence despite geopolitical uncertainties.

Reported metrics

Guidance from management

Management maintained guidance for organic net sales growth of 3% to 5% for 2026, adjusted for the phaseout of the Surgical Perfusion product category, indicating confidence in underlying demand despite geopolitical uncertainties.

What management said

We don't guide on and disclose gross margin levels on any of our products and Cardiohelp is no exception. Generally though, when we work with product development and new launches, we make sure that the products that -- from the next generation of any therapy or product category have a better gross margin than the category -- the generation that they replace, and Cardiohelp II should be no exception to this.

Yes, I think you're right. We said that they peaked at about SEK 800 million in 2024. We saw a small decrease in 2025. We expect another small decrease this year and then a slightly bigger decrease from 2027 onwards. And the end game here is to at least halve those costs.

What analysts pressed on

Analysts expressed concerns about the ongoing headwinds from tariffs and currency impacts on margins. There were also questions regarding the sustainability of growth in Acute Care Therapies and the potential impact of product launches on gross margins.

Main topics on the call

• Organic Sales Growth — Getinge achieved organic net sales growth of 0.8%, with a notable 3.9% increase in order intake. CEO Mattias Perjos stated, "We managed to beat last year's record quarter and grow top line organically."
• Impact of Tariffs and Currency — The company faced significant headwinds from tariffs and currency fluctuations, which negatively impacted adjusted EBITDA by SEK 226 million. CFO Agneta Palmer noted, "Even so, we managed to hold up margins, thanks to co...
• Product Launches and Approvals — Getinge announced the CE approval for Cardiohelp II, enhancing its ECLS therapy offerings. The product is expected to launch fully in Q3 2026, with positive reception noted by management.
• Financial Position and Cash Flow — The company reported a strong financial position with free cash flow of SEK 842 million and a leverage ratio of 1.5x adjusted EBITDA, well below the internal threshold of 2.5x. Management emphasized, "Our financial posit...

Read the full Getinge AB (publ) transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 33 Getinge AB (publ) earnings call transcripts on record, spanning January 30, 2020 to September 15, 2026. Based on this history, Getinge AB (publ) reports quarterly. The most recent call on file is dated September 15, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

GETIB

Exchange

OM

Country

SE

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

33

First call

January 30, 2020

Most recent

September 15, 2026

Reporting cadence

quarterly